References
- Dann E J, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905–909
- Horning S J, Chao N J, Negrin R S, Hoppe R T, Long G D, Hu W W, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813
- Moskowitz C H, Nimer S D, Zelenetz A D, Trippett T, Hedrick E E, Filippa D A, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616–623
- Moskowitz C H, Kewalramani T, Nimer S D, Gonzalez M, Zelenetz A D, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652
- Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2619
- Mackey J R, Mani R S, Selner M, Mowles D, Young J D, Belt J A, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349–4357
- Marcé S, Molina-Arcas M, Villamor N, Casado F J, Campo E, Pastor-Anglada M, et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006; 91: 895–902
- Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young J D, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956–6961
- Bartlett N L, Niedzwiecki D, Johnson J L, Friedberg J W, Johnson K B, van Besien K, et al. Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071–1079
- Lai R, Bartlett N L, Mackey J R, Jung S-H, Johnson J L, Cook J R, et al. High expression of nucleoside transporter protein hENT1 in Reed–Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin – A CALGB 59804 correlative study Leuk Lymph 2008; 49: 1202–1205
- Coe I, Zhang Y, McKenzie T, Naydenova Z. PKC regulation of the human equilibrative nucleoside transporter, hENT1. FEBS Lett 2002; 517: 201–215
- Fernández Calotti P, Galmarini C M, Cañones C, Gamberale R, Saénz D, Avalos J S, et al. Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochem Pharmacol 2008; 75: 857–865
- Iwasaki H, Huang P, Keating M J, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270–278
- Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res 2007; 55: 343–349
- Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457–463